Alere expands POC diabetes offering with Arriva buy
This article was originally published in Clinica
IVD company Alere has bulked up its point-of-care (POC) diabetes offerings with the acquisition of Arriva Medical, a specialist in home delivery of diabetes testing supplies. The transaction, which is subject to working capital and other closing adjustments entails a $65m cash payment plus 806,452 restricted shares of Alere stock.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.